Regeneron Pharma 3Q Sales Climb on Dupixent Growth

What happened

Regeneron said third-quarter revenue rose 36% to $5.12 billion, beating the $4.56 billion analysts expected, as Dupixent, Eylea HD and Libtayo each reached record net sales. Profit was $1.95 billion, or $18.45 a share. The stock gained 13% to $924.17.

Confirmed

Global impact / market context

Dupixent sales flow to Sanofi, which records global net product sales, while Regeneron takes a share of profits. That means faster Dupixent growth lifts Regeneron's revenue and profit without the full cost of selling the drug, supporting earnings per share.

Analyst inference

The 13% stock jump shows investors were positioned for less. Revenue beat expectations, and shares are up 20% this year. A pending Food and Drug Administration decision on cemdisiran, plus about 50 pipeline candidates, keeps attention on future drugs, not just current sales.

Analyst inference

What to watch

1. Regeneron expects a US Food and Drug Administration decision next month on cemdisiran for generalized myasthenia gravis, a muscle weakness condition. An approval would add a new product and revenue stream beyond Dupixent, Eylea HD and Libtayo. Confirmed
2. The companies this month expanded their long-standing immunology collaboration to include four additional Regeneron-invented drugs. Watch for terms on how costs, profits and sales responsibilities are divided, since Dupixent already shows how shared economics affect Regeneron's reported revenue. Proposed
3. Dupixent, Eylea HD and Libtayo all hit record sales, so future growth depends on whether those records keep rising. Slower Dupixent growth would cut Regeneron's profit share, while pipeline spending on roughly 50 candidates raises costs before any revenue arrives. Analyst inference

Evidence

• Original source link unavailable